Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0859 · 2 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| MK0859 | DRUG | - |
Inclusion Criteria: * You are between the ages of 45-75 * You are a man or non-pregnant woman * You agree to not eat or drink fruit or fruit juices (orange, apple or grapefruit) for 2 weeks before starting study medication Exclusion Criteria: * You have smoked or used other nicotine-containing pr...
MK0859 is an investigational small molecule being studied for use in ambulatory blood pressure and hypercholesterolemia. It is being developed by Merck & Company, Inc. (MRK) and is currently in Phase 1 clinical development.
MK0859 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and effects.
MK0859 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and efficacy.
MK0859 has been studied in two completed Phase 1 trials. NCT00565006 investigated its influence on blood pressure in healthy volunteers aged 45 years and older, while NCT00565292 studied it in patients with primary hypercholesterolemia or mixed hyperlipidemia.
No alternative names for MK0859 have been disclosed. It is identified solely by its development code MK0859 in clinical trial registries and by its developer, Merck & Company, Inc.